Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis

被引：70
|
作者：
Ahlawat, Shivani [1 ]
Blakeley, Jaishri O. [2 ,3 ]
Langmead, Shannon [2 ]
Belzberg, Allan J. [3 ]
Fayad, Laura M. [1 ,4 ,5 ]
机构：
[1] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, 601 North Caroline St,JHOC 3rd Floor, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
来源：
SKELETAL RADIOLOGY | 2020年 / 49卷 / 02期
关键词：
Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Schwannomatosis (SWN); Magnetic resonance imaging (MRI); Diffusion-weighted imaging (DWI); Apparent diffusion coefficient (ADC) values; Imaging biomarkers; Malignant peripheral nerve sheath tumor (MPNST); NERVE SHEATH TUMORS; WHOLE-BODY MRI; POSITRON-EMISSION-TOMOGRAPHY; BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TERM-FOLLOW-UP; PLEXIFORM NEUROFIBROMAS; BREAST-CANCER; DIAGNOSTIC-CRITERIA; F-18-FDG PET/CT; FDG-PET;
D O I：
10.1007/s00256-019-03290-1
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are three clinically distinct tumor predisposition syndromes with a shared tendency to develop peripheral and central nervous system neoplasms. Disease expression and complications of NF1, NF2, and SWN are highly variable, necessitating a multidisciplinary approach to care in order to optimize outcomes. This review will discuss the imaging appearance of NF1, NF2, and SWN and highlight the important role that imaging plays in informing management decisions in people with tumors associated with these syndromes. Recent technological advances, including the role of both whole-body and localized imaging strategies, routine anatomic and advanced magnetic resonance (MR) imaging sequences such as diffusion-weighted imaging (DWI) with quantitative apparent diffusion coefficient (ADC) mapping, and metabolic imaging techniques (MR spectroscopy and positron emission testing) are discussed in the context of the diagnosis and management of people with NF1, NF2, and SWN based on the most up-to-date clinical imaging studies.
引用
收藏
页码：199 / 219
页数：21
相关论文
共 50 条
  • [31] Neurofibromatosis type 1
    David H. Gutmann
    Rosalie E. Ferner
    Robert H. Listernick
    Bruce R. Korf
    Pamela L. Wolters
    Kimberly J. Johnson
    Nature Reviews Disease Primers, 3
  • [32] Neurofibromatosis type 1
    Soussi, T
    BULLETIN DU CANCER, 1999, 86 (06) : 515 - 516
  • [33] Neurofibromatosis type 1
    Ho, T-H
    Lee, J-T
    Liu, T-C
    Lin, J-C
    Yang, F-C
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2019, 112 (04) : 307 - 307
  • [34] Neurofibromatosis type 1
    Ferrer, Elisa
    Moral, Ma Angels
    Bozzo, Jordi
    DRUGS OF THE FUTURE, 2007, 32 (04) : 375 - 384
  • [35] Neurofibromatosis type 1
    Nature Reviews Disease Primers, 3 (1)
  • [36] Neurofibromatosis type 1
    Anders, Rebecca
    Hirsch, Franz Wolfgang
    Roth, Christian
    PAEDIATRIE UND PAEDOLOGIE, 2024, 59 (02): : 95 - 103
  • [37] Neurofibromatosis type 1
    North, K
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2000, 97 (02): : 119 - 127
  • [38] Neurofibromatosis type 1
    Gutmann, David H.
    Ferner, Rosalie E.
    Listernick, Robert H.
    Korf, Bruce R.
    Wolters, Pamela L.
    Johnson, Kimberly J.
    NATURE REVIEWS DISEASE PRIMERS, 2017, 3
  • [39] Neurofibromatosis type 1
    Mansilla-Polo, Miguel
    MEDICINA CLINICA, 2025, 164 (02): : 107 - 108
  • [40] Neurofibromatosis type 1
    Morse, RP
    ARCHIVES OF NEUROLOGY, 1999, 56 (03) : 364 - 365
12345